Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Seminars in Arthritis and Rheumatism Année : 2019

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis

Anne Musters
  • Fonction : Auteur
Carla Ann Wijbrandts
  • Fonction : Auteur
Marieke Herenius
  • Fonction : Auteur
Sytske Anne Bergstra
Sylvie Chollet-Martin
  • Fonction : Auteur
  • PersonId : 989986
Naoimh Donnellan
  • Fonction : Auteur
Julie E Davidson
  • Fonction : Auteur
Pierre Dönnes
  • Fonction : Auteur
Niek de Vries
  • Fonction : Auteur

Résumé

OBJECTIVES:To evaluate the incidence of anti-drug antibody (ADA) occurrences and ADA-related risk factors under adalimumab and infliximab treatment in rheumatoid arthritis (RA) patients.METHODS:The study combined retrospective cohorts from the ABIRISK project totaling 366 RA patients treated with adalimumab (n = 240) or infliximab (n = 126), 92.4% of them anti-TNF naive (n = 328/355) and 96.6% of them co-treated with methotrexate (n = 341/353) with up to 18 months follow-up. ADA positivity was measured by enzyme-linked immunosorbent assay. The cumulative incidence of ADA was estimated, and potential bio-clinical factors were investigated using a Cox regression model on interval-censored data.RESULTS:ADAs were detected within 18 months in 19.2% (n = 46) of the adalimumab-treated patients and 29.4% (n = 37) of the infliximab-treated patients. The cumulative incidence of ADA increased over time. In the adalimumab and infliximab groups, respectively, the incidence was 15.4% (5.2-20.2) and 0% (0-5.9) at 3 months, 17.6% (11.4-26.4) and 0% (0-25.9) at 6 months, 17.7% (12.6-37.5) and 34.1% (11.4-46.3) at 12 months, 50.0% (25.9-87.5) and 37.5% (25.9-77.4) at 15 months and 50.0% (25.9-87.5) and 66.7% (37.7-100) at 18 months. Factors associated with a higher risk of ADA development were: longer disease duration (1-3 vs. < 1 year; adalimumab: HR 3.0, 95% CI 1.0-8.7; infliximab: HR 2.7, 95% CI 1.1-6.8), moderate disease activity (DAS28 3.2-5.1 vs. < 3.2; adalimumab: HR 6.6, 95% CI 1.3-33.7) and lifetime smoking (infliximab: HR 2.7, 95% CI 1.2-6.3).CONCLUSIONS:The current study focusing on patients co-treated with methotrexate for more than 95% of them found a late occurrence of ADAs not previously observed, whereby the risk continued to increase over 18 months. Disease duration, DAS28 and lifetime smoking are clinical predictors of ADA development.
Fichier principal
Vignette du fichier
S0049017218301768.pdf (708.71 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02566700 , version 1 (25-10-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Jocelyn Quistrebert, Signe Hässler, Delphine Bachelet, Cyprien Mbogning, Anne Musters, et al.. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Seminars in Arthritis and Rheumatism, 2019, 48 (6), pp.967-975. ⟨10.1016/j.semarthrit.2018.10.006⟩. ⟨hal-02566700⟩
91 Consultations
130 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More